PPARGC1A and familial dilated cardiomyopathy: Generally, as a potential therapeutic target, PGC-1α is beneficial for reducing DCM cardiac injury by enhancing the mitochondrial biosynthesis of cardiomyocyte in the context of exercise intervention (Figure 7).